Apeloa Pharmaceutical Co Ltd

Apeloa Pharmaceutical Co Ltd maintains a relatively balanced capital structure, with a debt-to-equity ratio of 0.29, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.47, suggesting it has sufficient short-term assets to cover its short-term liabilities, but not in excess. Free cash flow stands at 337.88 million CNY, which is lower than the operating cash flow of 1.22 billion CNY, reflecting capital expenditures of 386.21 million CNY. Profitability metrics show that Apeloa Pharmaceutical Co Ltd has a return on equity (ROE) of 14.05% and a return on assets (ROA) of 7.23%. These figures are strong and suggest the company is effectively utilizing its equity and assets to generate returns. The gross profit margin is 25.42% (2.49 billion CNY gross profit on 9.78 billion CNY revenue), and the operating margin is 10.93% (1.07 billion CNY operating income on 9.78 billion CNY revenue), both of which are indicative of a healthy and efficient business model. Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, as a pharmaceutical company, it is likely that its operations are concentrated in China, given its listing on the Shenzhen Stock Exchange. The company's exposure to specific geographic regions or product segments is not detailed in the provided financial data. The company's growth trajectory is not explicitly outlined in the available data, but the current revenue of 9.78 billion CNY and the positive net income of 890.68 million CNY suggest a stable and profitable business. Analysts have provided a mean price target of 19.60 CNY, with a median of 19.60 CNY, indicating a generally positive outlook. The mean recommendation of 1.80 (on a scale from 1 to 5) further supports this, with 1 being strong buy and 5 being strong sell. Risk factors for Apeloa Pharmaceutical Co Ltd include a medium liquidity risk, as noted in the risk assessment. The company has a net cash position that is negative after subtracting total debt, which could pose a challenge in the event of unexpected cash flow disruptions. The dilution risk is assessed as low, and there are no immediate signs of dilution pressure in the near term. The company has not issued additional shares recently, and there is no indication of a pending dilutive event. Recent events and filings for Apeloa Pharmaceutical Co Ltd are not detailed in the provided data. However, the company's financial performance and analyst recommendations suggest a stable and well-managed business. The company's ability to maintain a positive net income and generate consistent cash flows indicates a strong operational foundation.